Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting inthe EU: Hands-on training course using the EudraVigilance System, Online, from 13 April 2026 to 17 April 2026

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting inthe EU: Hands-on training course using the EudraVigilance System, Online, from 18 May 2026 to 22 May 2026

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting inthe EU: Hands-on training course using the EudraVigilance System, Online, from 15 June 2026 to 19 June 2026

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting inthe EU: Hands-on training course using the EudraVigilance System, Online, from 26 January 2026 to 30 January 2026

Guidance on good manufacturing practice and good distribution practice: Questions and answers

How to submit information on authorised and investigational medicines

Draft user manual for the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) user interface (XEVMPDweb)

EMA/PE/0000183758

Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0012/2024

Opinion/decision on a Paediatric investigation plan (PIP): Rxulti, brexpiprazole, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Psychiatric disorders, PIP number: EMA/PE/0000183866